Asztma: nyitott vizsgálatok itt: Románia
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
1. fázisToborozTrial-stage medicine
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
- Where
- Bucharest, Cluj-Napoca
- Age
- 18 év to 65 év
- People
- 84 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06433921EU 2024-511220-14-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- Where
- Brasov, Bucharest, Cluj-Napoca, Craiova, Oradea, Timisoara, Timis
- Age
- 12 év to 80 év
- People
- 786 worldwide
- Run by
- Generate Biomedicines
See details and how to joinNCT07276724EU 2025-521950-41-00Regiszter frissítve: 2026-10-22
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- Where
- Bucharest
- Age
- 6 év to 11 év
- People
- 200 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05562466EU 2022-501899-26-00Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
- Where
- Bucharest
- Age
- 12 év to 17 év
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05776927Regiszter frissítve: 2026-10-15
3. fázisToborozTrial-stage medicine
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- Where
- Bucharest
- Age
- 5 év to 11 év
- People
- 231 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06023589Regiszter frissítve: 2026-10-13
2. fázisToborozTrial-stage medicine
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
- Where
- Brasov, Craiova, Timișoara
- Age
- 18 év to 75 év
- People
- 264 worldwide
- Run by
- Kymera Therapeutics, Inc.
See details and how to joinNCT07323654Regiszter frissítve: 2026-10-06
2. fázisToborzás még nem indultResearch participation
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
- Where
- Brasov, Craiova, Timisoara
- Age
- 18 év and over
- People
- 77 worldwide
- Run by
- Kymera Therapeutics Inc.
See details and how to join2026-526241-98-00EU 2026-526241-98-00Regiszter frissítve: 2026-09-23
2. fázisToborozResearch participation
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma
- Where
- Brasov, Craiova, Timisoara
- Age
- 18 év and over
- People
- 121 worldwide
- Run by
- Kymera Therapeutics Inc.
See details and how to join2025-523180-38-00EU 2025-523180-38-00Regiszter frissítve: 2026-09-03
3. fázisToborozTrial-stage medicine
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
- Where
- Brasov, Bucharest, Craiova
- Age
- 12 év and over
- People
- 456 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07456033EU 2025-524463-20-00Regiszter frissítve: 2026-08-17
3. fázisToborozResearch participation
A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
- Where
- Bucharest
- Age
- Up to 17 év
- People
- 68 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2022-502365-26-00EU 2022-502365-26-00Regiszter frissítve: 2026-08-04
4. fázisToborozTrial-stage medicine
BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])
- Where
- Bragadiru, Bucharest, Cluj-Napoca, Craiova, Iasi, Timisoara
- Age
- 18 év and over
- People
- 644 worldwide
- Run by
- Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07666490EU 2025-524289-56-00Regiszter frissítve: 2026-07-31
2. fázisToborozTrial-stage medicine
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
- Where
- Craiova
- Age
- 18 év to 75 év
- People
- 512 worldwide
- Run by
- Kinaset Therapeutics Inc
See details and how to joinNCT07532265EU 2023-509125-41-00Regiszter frissítve: 2026-07-28
2. fázisToborozTrial-stage medicine
Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
- Where
- Bacau, Bragadiru, Brasov, Bucaresti, Bucharest, Cluj-Napoca, Craiova, Deva, Oradea, Timisoara, Timișoara
- Age
- 18 év to 75 év
- People
- 780 worldwide
- Run by
- Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07301736EU 2025-521456-35-00Regiszter frissítve: 2026-06-25
No phaseToborzás még nem indultResearch participation
Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma
- Where
- Brasov, Bucharest, Suceava, Timișoara
- Age
- 10 év to 19 év
- People
- 42
- Run by
- University Children's Hospital Basel
See details and how to joinNCT07472283Regiszter frissítve: 2026-03-16
Minden vizsgálat (Asztma) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.